HighTide Therapeutics, Inc., a Cayman-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, reported no changes in either its authorised or issued share capital for the month ended 31 May 2026.

• Authorised share capital: Remained at 1.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to total authorised capital of USD 0.10 million.

• Issued shares: Unchanged at 571.33 million ordinary shares; the company held no treasury shares, and there were no share repurchases or cancellations during the month.

• Capital-raising instruments: The issuer reported no activity under share option schemes, warrants, convertible securities, or other equity-related agreements.

• Public float: Management confirmed compliance with the Main Board’s minimum 25% float requirement as of 31 May 2026.

The monthly return was signed by Executive Director and CEO Dr. Liu Liping and submitted to Hong Kong Exchanges and Clearing Limited on 1 June 2026.